Valeant Pharmaceuticals says it will file Q1 results before deadline
Valeant Pharmaceuticals reaffirmed its first-quarter guidance on Monday and said it will file its results for the quarter well in advance of a July 31 deadline.
The Laval, Que.-based company said in a release it will file the results by June 10 with the U.S. Securities and Exchange Commission and Canadian securities regulators. The end of July deadline is tied to an agreement with the company's lenders.
The company also said it expects to file the results of its second quarter, and for subsequent quarters, on a "timely basis."
The reaffirmed guidance has Valeant expecting to make between $1.30 to $1.55 per share for the quarter.
In late April, Valeant filed long-overdue results from 2015 as it wrestles with a number of government investigations and a plunging stock price.
- Warren Buffett calls Valeant strategy 'flawed'
- Valeant Pharmaceuticals blasted by U.S. lawmakers over drug price hikes
Shares of Valeant initially opened higher on the NYSE and TSX on Monday morning, but subsequently retreated. On the NYSE, the stock finished lower by $1.82 at $28.07 US, while the stock was down $2.02 at $36.56 on the TSX.